Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 190

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 190
---
 or omissions, there are no underwriters of the ParentCo Common Stock and ParentCo warrants that will be issued pursuant to the registration statement of which this proxy statement/prospectus forms a part and thus no corresponding right of action is available to investors in the Business Combination for any material misstatements or omissions in such registration statement. Therefore, as an investor in the Business Combination, you may be exposed to future write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative impact on ParentCo’s financial condition and its share price, which could cause you to lose some or all of your investment without certain recourse against any underwriter that may be available in an underwritten offering.

Iris may not be able to realize the anticipated benefits from the Business Combination.

The successful completion of the Business Combination may not yield the anticipated benefits or the benefits may not occur in the anticipated time frame. Moreover, the ability to realize the benefits in the expected time frame may be materially adversely affected by a number of factors. The proposed Business Combination to date has placed, and future acquisitions could continue to place, significant demands on both Liminatus’s and Iris’s administrative, operational and financial resources and may also result in the assumption of unexpected liabilities and may divert management’s attention from the operation of Liminatus’s business.

<div align='center'>81</div>

TABLE OF CONTENTS

Additionally, strategic investments and partnerships with other companies may expose ParentCo to the risk that it may not be able to control the operations of the investee or partnership, which could decrease the amount of benefits ParentCo realizes from a particular relationship. ParentCo will also be exposed to the risk that its partners in strategic investments may encounter financial difficulties that could lead to disruption of investee or partnership activities, or impairment of assets acquired, which could materially adversely affect future reported results of operations and financial condition.

Nasdaq may not agree to list ParentCo’s securities from trading on its exchange, which could limit investors’ ability to make transactions in ParentCo’s securities and subject us to additional trading restrictions.

Iris cannot assure that ParentCo’s securities will be listed on Nasdaq after the Business Combination. In order to continue listing ParentCo’s securities on Nasdaq after the Business Combination, ParentCo must maintain certain financial, distribution and stock price levels. Generally, ParentCo must maintain a minimum amount in stockholders’ equity and a minimum number of holders of ParentCo’s securities. Additionally, in connection with the Business Combination, ParentCo will be required to